Documented prevalence of HIV type 1 antiretroviral transmitted drug resistance in Ireland from 2004 to 2008

AIDS Research and Human Retroviruses

Volumn 28, Issue 3, 2012, Pages 276-281

  De Gascun, Cillian F ^a   Waters, Allison ^a   Regan, Ciara ^a   O'Halloran, Jane ^b   Farrell, Gillian ^c   Coughlan, Suzie ^a   Bergin, Colm ^c   Powderly, William G ^a   Hall, William W ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IRELAND; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RNA SEQUENCE; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; IRELAND; MALE; MUTATION; PHYLOGENY; PREVALENCE; PUBLIC HEALTH; RNA, VIRAL; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, RNA;

EID: 84858128537     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0166     Document Type: Article

References (21)

1. Gao F, Bailes E, Robertson DL, et al.: Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397(6718):436-441.
2. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21(2):215-223. (Pubitemid 46036930)
3. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15(2): 247-277. (Pubitemid 34303765)
4. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004;9(6):829-48. (Pubitemid 40040258)
5. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4(3):e4724.
6. Magiorkinis E, Detsika, M., and Paraskevis, D: Monitoring HIV drug resistance in treatment-naive individuals: Molecular indicators, epidemiology, and clinical implications. HIV Ther 2009;3(4):369-390.
7. Vercauteren J, Wensing AM, van de Vijver DA, et al.: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200(10):1503- 1508.
8. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192(6):958-966. (Pubitemid 41266791)
9. Maguire C, Ni Cheallaigh C, De Gascun CF, et al.: Anti-retroviral prescribing for HIV-positive injection drug users and effects on patient outcome. HIV Med 2008;9(Suppl. 1):22.
10. Gazzard BG: British HIV Association Guidelines for the treatment of HIV-1 infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608.
11. Thompson MA, Aberg JA, Cahn P, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 2010; 304:321-333.
12. Durant J, Clevenbergh P, Halfon P, et al.: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353(9171):2195-2199. (Pubitemid 29295252)
13. Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma geno-typic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14(9):F83-93. (Pubitemid 30420686)
14. Chaix ML, Desquilbet L, Descamps D, et al.: Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 2007;12:1305-1310.
15. Little SJ, Holte S, Routy JP, et al.: Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394. (Pubitemid 34851830)
16. Oette M, Kaiser R, Daumer M, et al.: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Def Syndr 2006;41:573-581.
17. Bartmeyer B, Keucherer C, Houareau C, et al.: Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Ser-oconverter Cohort. PLoS One 2010;5:e12718.
18. Wittkop L, Gunthard HF, de Wolf F, et al.: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multi-cohort study. Lancet Infect Dis 2011;11:363-371.
19. Peuchant O, Thiebaut R, Capdepont S, et al.: Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008;22:1417-1423.
20. Li JZ, Paredes R, Ribaudo HJ, et al.: Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based anti-retroviral treatment failure: A systemic review and pooled analysis. JAMA 2011;305(13):1327-1335.
21. Weinstein MC, Goldie SJ, Losina E, et al.: Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134(6):440-450. (Pubitemid 32225945)